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Pharmacoresistant Ca2+ channelPeptide-hormone secretion is partially triggered by Ca2+ inﬂux through voltage-gated Ca2+ channels (VGCCs)
and gene inactivation of Zn2+-sensitive Cav2.3-type VGCCs is associated with disturbed glucose homeostasis in
mice. Zn2+ has been implicated in pancreatic islet cell crosstalk and recent ﬁndings indicate that sudden cessa-
tion of Zn2+ supply during hypoglycemia triggers glucagon secretion in rodents. Here we show that
diethyldithiocarbamate (DEDTC), a chelating agent for Zn2+ and other group IIB metal ions, differentially affects
blood glucose and serum peptide hormone level in wild-type mice and mice lacking the Cav2.3-subunit. Fasting
glucose and glucagon level were signiﬁcantly higher in Cav2.3-deﬁcient compared to wild-type mice, while
DEDTC Zn2+-chelation produced a signiﬁcant and correlated increase of blood glucose and serum glucagon con-
centration inwild-type but not Cav2.3-deﬁcientmice. Glucose tolerance tests revealed severe glucose intolerance
in Zn2+-depleted Cav2.3-deﬁcient but not vehicle-treated Cav2.3-deﬁcient or Zn2+-depleted wildtype mice. Col-
lectively, these ﬁndings indicate that Cav2.3 channels are critically involved in the Zn2+-mediated suppression of
glucagon secretion duringhyperglycemia. Especially under conditions of Zn2+ deﬁciency, ablation or dysfunction
of Cav2.3 channels may lead to severe disturbances in glucose homeostasis.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Ionic zinc (Zn2+) is required for proper formation, processing and
crystallization of insulin in β-cell secretory granules [1,2], and co-
secreted with insulin during hyperglycemia [3]. In addition to its role
for β-cell function, Zn2+ is increasingly recognized as a possible auto-
and paracrine signaling molecule involved in pancreatic islet cell
crosstalk. Zn2+ concentrations co-released into the extracellular space
during hyperglycemia are estimated to be in the order of several hun-
dred μmol/l [3], so that nearby cells are exposed to high levels of
unbound Zn2+. A number of in vitro and in vivo studies have implicated
Zn2+ in the feedback regulation of β-cell insulin secretion, but the exact
physiological relevance of these ﬁndings remains a matter of debate.
Recent results moreover demonstrate that sudden cessation of Zn2+
supply during glucose deprivation triggers glucagon release in isolated
mouse and rat islets and in living rats, suggesting that Zn2+ serves as
a switch-off signal for glucagon secretion during hypoglycaemia [4–6].+49 221 478 6965.
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tario N6A 5C1, Canada.Zn2+-induced changes in α- and β-cell function have been shown or
proposed to involve activation of ATP-sensitive K+ (KATP) channels
[4–7], but the relevance of other zinc-binding targets in endocrine
cells has not been established. Besides weakly blocking all voltage-
gated Ca2+ channels (VGCCs) [8], Zn2+ is a potent allosteric antagonist
of certain Cavα1 subunits (Cav2.3 and Cav3.2), which possess extracellu-
lar metal binding sites with nanomolar to lowmicromolar Zn2+ afﬁnity
[9–13]. Since Cav2.3 VGCCs have been linked to insulin [14–16], gluca-
gon [17], and somatostatin (SST) release in mice [18], we compared
the effects of Zn2+ chelation on glucose homeostasis and peptide hor-
mone release in Cav2.3-deﬁcient and control mice. Due to an unexpect-
edly high glucose-tolerance of Cav2.3-deﬁcientmice, we also reassessed
glucose tolerance and glucose-stimulated insulin secretion (GSIS) in
vivo and in isolated islets of Langerhans.
2. Materials & methods
2.1. Animals
Mice were housed at a constant temperature (22 °C–23 °C), with
light on from 7 a.m. to 7 p.m. and ad libidum access to food and water
as described previously [15]. They were fed a breeding diet containing
22.5% crude protein, 5% crude fat, and 4.5% crude ﬁber (Altromin,
Lage, Germany).
The cacna1e gene encoding Cav2.3 was disrupted in vivo by agouti-
colored Cav2.3(ﬂ|+) and delete mice expressing Cre-recombinase
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tion. Cav2.3-deﬁcient mice were fertile, exhibited no obvious behavioral
abnormalities andhad the same lifespan as controlmice. Parallel breeding
of parental inbred mouse lines of Cav2.3-deﬁcient and control mice
ensured their identical background. Number, age and mean body weight
of mice used in the different experiments are summarized in Table 1.
During the experiments mice were fasted with free access to water.
The animal experimentation described in the text was approved by the
institutional committee on animal care and conducted in accordance
with accepted standards of humane animal care, as described in the
UFAW handbook on the care and management of laboratory animals.
2.2. Glucose tolerance tests and serum insulin measurements
After a 14 h fasting period, glucose tolerance testswere performed in
5 and 10 weeks old mice by a single intraperitoneal (i.p.) injection of
glucose (2 mg/g body weight) and sampling of glucose levels in tail
vein blood obtained by small tail cuts immediately before and 15 min,
30 min, 60 min, and 120 min after the glucose injection. Blood glucose
concentration was determined using the Glucometer Elite (Bayer
Diagnostics GmbH, Germany). In 10 week old animals, serum insulin
level was quantiﬁed in blood samples taken immediately before
(=time point 0) and 2 min, 5 min, 15 min, 30 min, 60 min and
120 min after the glucose injection by the enzyme-linked immunosor-
bent assay (ELISA) kit from Crystal Chem Inc. (Chicago, USA) using
mouse insulin as a reference. To investigate the effects of Zn2+-
chelation on glucose tolerance, 14–17 week old mice were fasted for
7.25 h and i.p. injections of the Zn2+ chelator diethyldithiocarbamate
(DEDTC, sodium salt trihydrate, 0.15 mg/g; Sigma Aldrich) or 0.9%
NaCl (Berlin-Chemie AG, Berlin, Germany) were carried out 75 min,
105 min, 165 min, 195 min and 285 min after the start of the fasting
period. Glucose was injected 150 min after the last DEDTC treatment
and blood glucose concentration measured as described above using
the GlucoMen Glycó (Berlin-Chemie AG, Germany).
2.3. Isolation of islets of Langerhans for insulin secretion assays
17–24 week old mice were anesthetized by intraperitoneal injec-
tion of ketamine/xylazine. A mixture of 2 ml ketamine stock solution
(25mg/ml) and 0.25ml 2% xylazine, dilutedwith 3ml 0.9% NaCl, was
injected intraperitoneally (0.01 ml per gram body weight). The mix-
ture was stored at 4 °C for maximal ten days. Pancreatic islets were
isolated by a collagenase digestion protocol modiﬁed after Gotoh
et al. [19]. Brieﬂy, the pancreas was removed after slow ductal injec-
tion of 3 ml collagenase (3 mg/ml) in cold Hanks buffered salt solu-
tion (HBSS) containing (in mM) 137 NaCl, 5 KCl, 0.8 MgSO4, 0.34
Na2HPO4, 0.44 KH2PO4, 4.2 NaHCO3, 1.26 CaCl2, 2 D-glucose, and 10
HEPES (pH = 7.25) and supplemented with 6.26 mM CaCl2. After
19 min incubation at 37 °C in 0.5 ml HBSS, digestion was stoppedTable 1
Gender, age and body weight of mice used in the different experiments. Data are mean
values ± SEM. GTT, glucose tolerance tests; II, islet isolation.
Gender Age
[weeks]
Genotype Body weight
[g]
n Experiment
Female 14–17 Wildtype 20.7 ± 1.5 25 DEDTC
Cav2.3(−/−) 24.5 ± 1.7 27 DEDTC
Male 5 Wildtype 21.5 ± 1.5 8 GTT
Cav2.3(−/−) 18.7 ± 1.3 8 GTT
10 Wildtype 25.9 ± 1.2 8 GTT
Cav2.3(−/−) 23.8 ± 0.9 8 GTT
14–17 Wildtype 24.5 ± 0.9 9 DEDTC
Cav2.3(−/−) 25.9 ± 1.4 8 DEDTC
17–24 Wildtype 27.9 ± 0.5 8 II
Cav2.3(−/−) 29.5 ± 1.8 7 IIby addition of 30 ml cold HBSS supplemented with 0.3% BSA. Follow-
ing mechanical disruption at 4 °C and removal of undigested tissue,
islets were transferred on ice, collected under a dissection micro-
scope and allowed to recover for 22 h in RPMI culture medium
supplemented with 10% FBS, 1 mM L-glutamine, 100 U/ml penicillin,
100 μg/ml streptomycin and 0.1% BSA at 37 °C and 5% CO2.
Insulin secretion was investigated in static batch incubations of
three to ﬁve islet sets per mouse. Each set contained the same number
of size-matched islets, consisting of one large (200–250 μm), six to ten
intermediate (110–170 μm) and one small (70–90 μm) islet. After a
30 min equilibration period, islets were incubated for 55 min at 37 °C
in Krebs–Ringer buffer (KRB) containing (in mM) 120 NaCl, 4.2 KCl,
1.2 KH2PO4, 25 NaHCO3, 1.2 MgSO4, 2.5 CaCl2, 2.8 D-glucose and 10
HEPES (pH = 7.4). The medium was removed and stored at −20 °C
pending basal insulin secretion measurements, while the islets were
incubated for another 55 min at 37 °C in 0.5 ml KRB containing 20 mM
D-glucose. Following recovery of the medium for glucose-stimulated
insulin secretion measurements, islets were lysed by incubation for
15 min at 37 °C in 0.5 ml PBS containing 1% (v/v) Igepal CA-630, 0.5%
(w/v) Na-deoxycholate and 0.1% (w/v) SDS, and the resulting extract
used for quantiﬁcation of total protein and insulin content.
Insulin was quantiﬁed by the Insulin (Mouse) ELISA Kit from DRG
Instruments (Marburg, Germany) and total protein content by the
BCA Protein Assay Kit from Perbio Science Deutschland (Bonn,
Germany) using BSA as a reference.
2.4. Whole-cell patch clamp recordings
Human embryonic kidney (HEK-293) cells stably transfected with
human Cav2.3d and β3 subunits were cultured under normal growth
conditions (37 °C and 5% CO2) in Dulbecco's modiﬁed Eagle medium
(Sigma-Aldrich) supplementedwith 10% fetal calf serum and antibiotics
(1% penicillin–streptomycin and selection markers G-418 and
hygromycin B). For electrophysiological recordings, cells were seeded
on nitric acid-washed glass coverslips and used within 1 to 3 days
after plating. All recordings were performed at room temperature
using the whole-cell conﬁguration of the patch clamp technique [20].
Brieﬂy, cells were voltage-clamped with an EPC9 ampliﬁer (HEKA,
Germany) controlled by HEKA's Pulse software. Leak and capacitive
currentswere subtracted online by use of a−P/5 protocol and series re-
sistance (5–15 MΩ) compensated electronically by 65–85%. Pipettes
were prepared from thick-walled borosilicate glass capillaries (World
Precision Instruments) and had a resistance of 2–5 MΩ when ﬁlled
with internal solution. The standard external solution contained (in
mM) 120 NaCl, 5 BaCl2, 5 KCl, 1 MgCl2, 20 tetraethylammonium chlo-
ride, 10 glucose, 0.01 ZnCl2 and 10 HEPES (pH = 7.4). It was applied
to cells at a rate of 1–2 mlmin−1 using a gravity-driven 2-barreled per-
fusion system with two separate inlets, and the bath was connected to
ground by a 120 mM NaCl agar bridge. The internal solution contained
(in mM) 130 CsCl, 5 oxaloacetic acid, 5 creatine, 5 pyruvic acid, 10
ethyleneglycol-bis(ß-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA)
and 10 HEPES (pH = 7.3). All voltages were corrected for the liquid
junction potential of 5.5 mV (calculated using the JPcalc algorithm in
pClamp 10; Molecular Devices, Sunnyvale, CA) between internal and
external solution. DEDTC was prepared as 5 mM stock solution and
added to the standard external solution prior to recordings to make
the ﬁnal concentration given in the text. Currents were evoked by
brief voltage-steps from a holding potential of−80 mV to potentials
between −60 and 60 mV. Current–voltage (IV)-relationships were
constructed by plotting peak current amplitudes as a function of the
test potential and ﬁtted with a combined Ohm–Boltzmann equation:
I ¼ Vm−Vrevð Þ  Gmax= 1þ exp −Vm−V0:5ð Þ=dVð Þð Þ
where Vm is the test potential, I the peak current measured at the cor-
responding potential, Vrev the apparent reversal potential, Gmax the
Fig. 1. Effects of Cav2.3 channel ablation on glucose tolerance and insulin secretion in vivo.
A. Experimental protocol: Intraperitoneal glucose (2 mg/g) tolerance tests were
performed on 14h fasted Cav2.3-deﬁcient andwildtypemice. Blood glucose and serum in-
sulin level were quantiﬁed in blood samples taken from the tail vein immediately prior to
glucose challenge (timepoint 0) and at the indicated timepoints thereafter. B. Time course
of blood glucose disposal in 5 weeks old Cav2.3-deﬁcient and wild-type mice (n = 8 for
both genotypes). C. Same as in B, but measured in 10 weeks old mice (n= 8 for both ge-
notypes). D. Time course of changes in serum insulin level of 10weeks old Cav2.3-deﬁcient
and wild-type mice (same animals as in C). E. Comparison of blood glucose and serum in-
sulin level in 10weeks oldwild-type and Cav2.3-deﬁcientmice 30min after glucose injec-
tion (same data as in C and D). Statistically signiﬁcant differences are indicated by
footnotes and are by unpaired Student's t-test (**, p b 0.001; *, p b 0.05).
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rent activation and dV the slope factor. The voltage-dependence of
activation was determined from tail currents produced upon repo-
larization from different test potentials to−60 mV. Relative tail cur-
rent amplitude (I/Imax) was plotted as a function of the test potential
and ﬁtted with a single Boltzmann equation:
I=Imax ¼ 1= 1þ exp −Vm−V0:5actð Þ=dVactð Þð Þ
where V0.5act is the voltage of half-maximal activation and dVact the
activation slope factor. All ﬁts were performed with OriginLab Pro 9
(OriginLab, Northampton, MA) using the Levenberg–Marquardt
least-squares algorithm. Smooth curves in the ﬁgures represent ﬁts
to average data, while values given in the text are average data
from ﬁts to individual measurements.
2.5. Blood glucose homeostasis during DEDTC Zn2+ chelation
During a 5.25 h fasting period, three i.p. DEDTC injections (0.025mg/g
body weight each) were carried out 75 min, 105 min and 165 min after
the start of the fasting period in 14–17 week old mice. Blood glucose
level was monitored in blood samples obtained from the tail vein by
small tail cuts collected immediately before the ﬁrst DEDTC injection
(=time point 0) and 30 min, 60 min, 120 min and 180 min thereafter.
In some experiments, blood glucose was additionally measured 90 min
after the ﬁrst DEDTC injection. Whenever DEDTC injections and blood
collection were performed at the same time point, the blood sample
was obtained prior to the injection.
2.6. Peptide hormone homeostasis during DEDTC Zn2+ chelation
During a 3.25 h fasting period, two i.p. DEDTC injections (0.025mg/g
body weight each) were carried out 75 min and 105 min after of the
fasting period. Blood samples for quantiﬁcation of glucose and serum
peptide hormones were obtained from the tail vein by small tail cuts
collected immediately before the ﬁrst and 30 min after the second
DEDTC injection. Serum insulin was quantiﬁed as described above, glu-
cagon and SSTwere quantiﬁed using the Glucagon EIA kit (YK090) from
Yanaihara Institute Inc. (Awakura, Japan) and the extraction-free
somatostatin-14 EIA kit from Bachem Ltd. (St. Helens, Merseyside, UK)
respectively. Optical density in samples during the ELISA/EIA tests was
measured with the automatic microplate reader μQuant (Bio-Tek
Instruments, Germany). Data analysis based on the 4-parameter curve
ﬁt was performed using the KC4 2.5 software (Bio-Tek Instruments).
2.7. Statistical data analysis
All values mentioned in the text and shown in the ﬁgures and tables
are expressed as mean± standard error of the mean (SEM), based on n
the number of independent experiments. Smooth curves in Fig. 3 repre-
sent ﬁts to average data as described in Section 2.4. Statistical signiﬁ-
cance was calculated using Student's unpaired t-test (or Student's
paired t-test for electrophysiological recordings). Levels of p b 0.05
were considered as statistically signiﬁcant (*), and levels of
p b 0.001 as statistically highly signiﬁcant (**).
3. Results
3.1. Cav2.3-deﬁcient mice have preserved glucose tolerance despite im-
paired peripheral insulin response
Intraperitoneal glucose tolerance tests were performed in fasted
(14 h), 5 week old Cav2.3-deﬁcient mice and aged-matched wild-type
mice with identical genetic background (n = 8 for both genotypes)
(Fig. 1A). As illustrated in Fig. 1B, fasting blood glucose level was signif-
icantly lower in Cav2.3-deﬁcient mice (p b 0.001), but it reachedcomparable values in both genotypes 15 min after glucose injection.
Thereafter, absolute glucose excursion was similar in the two geno-
types, although the area under the curve (AUC) above baseline glucose
was approximately 25% higher in Cav2.3-deﬁcient mice. When the ex-
periment was repeated with the same number of 10 weeks old mice,
neither basal blood glucose level nor absolute glucose excursion
(Fig. 1C) or AUC above baseline glucose differed between the two geno-
types, possibly indicating age-dependent metabolic changes in one of
the two groups. However, serum insulin measurements revealed that
ablation of Cav2.3 channels was in fact associated with a markedly
diminished sustained insulin response in 10 weeks old mice, so that
30 min after glucose injection, serum insulin level had signiﬁcantly
increased to 335% of the basal level (p b 0.05) in wild-type mice but
only to 175% (p N 0.05) in Cav2.3-deﬁcient animals (Fig. 1D). This
impairment had surprisingly little effect on glucose tolerance (Fig. 1E),
suggesting that it is either masked by other effects of Cav2.3-deﬁciency
or offset by compensatory functional changes.
3.2. Isolated islets from Cav2.3-deﬁcient mice exhibit normal GSIS but basal
hyperinsulinemia and reduced insulin content
The lower peripheral insulin response in Cav2.3-deﬁcientmice could
result from reduced β-cell GSIS, increased peripheral insulin clearance
or changes in the extrinsic regulation of β-cell function. Therefore,
basal and glucose-stimulated insulin secretion was also characterized
in 55-min static batch incubations of isolated islets of Langerhans.
In seven independent experiments, islets were isolated from 17 to
22 week old male wild-type and Cav2.3-deﬁcient mice, and insulin se-
cretion, insulin content and total protein content measured in three to
ﬁve sets of size-matched islets per animal (Fig. 2A). Total protein
Fig. 2. Effects of Cav2.3 channel ablation on insulin content, basal insulin secretion and glucose-stimulated insulin secretion in isolated islets of Langerhans. Sets of size-matched islets were
isolated from wild-type and Cav2.3-deﬁcient mice, and characterized in 55-min static batch incubations. A. Representative set of isolated islets. B. Distribution of total protein content in
islets fromCav2.3-deﬁcient (n=26 assays in islets from7 animals) andwild-typemice (n=29 assays in islets from7 animals). C. Distribution of total insulin content in islets fromCav2.3-
deﬁcient andwild-typemice (same islets as in B). D. Distribution of basal insulin secretion in islets from Cav2.3-deﬁcient and wild-typemice measured in the presence of 2.8 mMglucose
(same islets as in B & C). E. Distribution of glucose-stimulated insulin secretion in islets from Cav2.3-deﬁcient and wild-typemice measured in the presence of 20mMglucose (same islets
as in B–D). F. Stimulation factor, calculated as the ratio of data in D and E. G. Same data as in F, but plotted as a function of basal insulin secretion. Statistically signiﬁcant differences are
indicated by footnotes and are by unpaired Student's t-test (*, p b 0.05).
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(Fig. 2B), but insulin content was signiﬁcantly lower (p b 0.05) in islets
from Cav2.3-deﬁcient mice, which had a mean insulin content corre-
sponding to approximately 74% of the insulin content inwild-type islets
(Fig. 2C). Surprisingly, insulin secretion in the presence of low glucose
(2.8 mM) also tended to be higher in islets from Cav2.3-deﬁcient mice
(Fig. 2D), indicating that they exhibit basal insulin hypersecretion.
This difference was abolished when the glucose concentration was
raised to 20 mM (Fig. 2E), so that the stimulation factor, calculated as
the ratio of insulin release in high vs. low glucose, was signiﬁcantly
higher (p b 0.05) in islets from wild-type mice (Fig. 2F).
The stimulation factor in individual islet assays from both genotypes
varied inverselywith basal insulin secretion, so that the response to glu-
cose stimulationwas stronger in isletswith lower basal insulin secretion
(Fig. 2G). Ablation of Cav2.3 channels enhanced basal islet insulin secre-
tion by 57% relative towild-typemice, thereby increasing the fraction of
islets with low response (i.e. 7 vs. 0 islets with stimulation factor b 2 in
Cav2.3-deﬁcient vs wild-type mice; lower blue area in Fig. 2G) and de-
creasing the fraction of islets with high response (i.e. 0 vs. 6 islets with
stimulation factor N 11 in Cav2.3-deﬁcient vs. wild-type mice; upper
blue area in Fig. 2G). Thus, Cav2.3-channel ablation attenuated the
ability of glucose to increase insulin secretion in isolated islets mainly
by increasing basal insulin secretion, while absolute secretion capacity
in high glucose was similar for islets from both genotypes (indicating
normal glucose responsiveness).
The lower peripheral insulin response of Cav2.3-deﬁcient mice
in vivo is apparently not related to reduced β-cell insulin secretion per
se, and may instead result from β-cell desensitization, changes in the
extrinsic regulation of β-cell function or increased peripheral insulin
clearance (but see discussion).
3.3. DEDTC Zn2+ chelation reverses tonic suppression of Cav2.3 channels
in vitro
A number of previous studies have implicated Zn2+ in the paracrine
regulation of β-cell function [21–24], and insulin hypersecretion in
ZnT8-deﬁcient mice has been linked to insufﬁcient suppression ofβ-cells due to reduced Zn2+ release [7]. In view of their exceptional
Zn2+ sensitivity (IC50(Zn2+) = 1–10 μM) [12], we hypothesized
that a lack of β-cell Cav2.3 channels may have similar functional conse-
quences and result in impaired feedback inhibition of insulin secretion.
To investigate the role of Cav2.3 channels for Zn2+ modulation of glu-
cose homeostasis in vivo, we used DEDTC, which is a relatively nontoxic
(doses up to 1mg/g b.w. are toleratedwell [25]) chelator routinely used
for experimental Zn2+ depletion in rodents. Effects of DEDTC Zn2+
chelation were also characterized in vitro using whole-cell patch
clamp recordings in HEK293 cells stably transfected with human
Cav2.3d and β3-subunits. As illustrated in Fig. 3A–C, addition of
100 μMDEDTC to the extracellular solution containing 10 μM Zn2+ po-
tently stimulated Ba2+ inward currents over the whole voltage-range
examined without changing the apparent reversal potential. Consistent
with a reversal of allosteric suppression by chelation of extracellu-
lar Zn2+ [12,13], DEDTC effects were associated with a signiﬁcant
(p b 0.001) hyperpolarizing shift of the half-maximal activation
voltage (Fig. 3C & D), they were rapid (Fig. 3E) and fully reversible
upon washout (Fig. 3B–E). When the same recordings were performed
in presence of the selective Zn2+–chelator Ca2+–EDTA (100 μM), all of
the above effects were abolished (Fig. 3F–H), conﬁrming that the action
of DEDTC was mediated by chelation of Zn2+ in the extracellular
solution.
3.4. Zn2+-depletion stimulates glucose mobilization and impairs glucose
tolerance in Cav2.3-deﬁcient mice
The in vivo effect of Zn2+ chelation on glucose tolerance was
assessed by intraperitoneal glucose challenge (2 mg/g body weight)
after ﬁve consecutive intraperitoneal injections of 0.15 mg/g b.w.
DEDTC in female, fasted mice (Fig. 4A). As illustrated in Fig. 4B, DEDTC
treatment had no effect on the kinetics of blood glucose disposal in
wild-typemice. Likewise, glucose tolerancewas not signiﬁcantly affect-
ed by ablation of Cav2.3 channels alone (i.e. see vehicle-treated Cav2.3-
deﬁcient mice in Fig. 4B & C). In contrast, DEDTC pre-treatment of
Cav2.3-deﬁcient mice was associated with severe glucose intolerance,
reﬂected in signiﬁcantly higher (p b 0.05) blood glucose levels relative
Fig. 3. Effects of Zn2+-chelation onwhole-cell Ba2+ currents through recombinant Cav2.3 channels recorded in the presence of 10 μMZn2+.Whole-cell currentswere recordedwith 5mM
Ba2+ as the charge carrier from perfused HEK-293 cells stably transfected with human Cav2.3d & β3 subunits. All recordings were performed in the presence of 10 μMnominal Zn2+ and
from a holding potential of−80mV. A. Representative families of current traces recorded in response to the protocol depicted above before (black) and after (orange) addition of 100 μM
DEDTC. B. Peak current–voltage (IV)-relationships obtained by the protocol depicted in A before (control) and after addition of 100 μMDEDTC and after washout. Values are normalized to
themaximum peak current observed under control conditions (n= 6). C. Voltage-dependence of steady-state activation, obtained by recording tail-current amplitudes upon repolariza-
tion from the indicated potentials to−60mV before (control) and after addition of 100 μMDEDTC and after washout (same cells as in B). D. Voltages of half-maximal activation, obtained
from Boltzmann ﬁts to the data in C. E. Time-course of acute DEDTC effects on peakwhole-cell currents evoked by step depolarization to 10mV. F. IV-relationships obtained as in B but in
the continued presence of the selective Zn2+ chelator Ca–EDTA (n= 7). G. Voltage-dependence of steady-state activation obtained as in C but in the continued presence of the selective
Zn2+ chelator Ca–EDTA (same cells as in F but n=6). H. Voltages of half-maximal activation, obtained fromBoltzmannﬁts to the data inG. Statistically signiﬁcant differences are indicated
by footnotes and are by paired Student's t-test (**, p b 0.001).
Fig. 4. Effects of Zn2+-depletion on glucose tolerance in Cav2.3-deﬁcient and wild-type
mice. A. Experimental protocol: After 6 h of fasting and pre-treatment with DEDTC
(5 × 0.15 mg/g, i.p., red arrows), animals received a single injection of D-glucose
(2 mg/g, i.p., blue arrow). Blood glucose level was quantiﬁed in blood samples
taken from the tail vein immediately prior to glucose challenge (time point 0) and
at the indicated time points thereafter. B. Time course of glucose excursion in
DEDTC- and vehicle-treated wild-type mice (n = 5 for both groups). C. Time course
of glucose excursion in DEDTC- (n = 6) and vehicle-treated (n = 4) Cav2.3-deﬁcient
mice. D. Time course of changes in blood glucose level during the fasting period
before glucose injection in vehicle-treated wild-type and Cav2.3-deﬁcient mice
(same mice as in B & C). E. Time course of changes in blood glucose level during the
fasting period before glucose injection in DEDTC-treated wild-type and Cav2.3-deﬁcient
mice. Values are normalized to the baseline level and data from vehicle-treated litter-
mates are also shown for comparison (same mice as in B & C).
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(Fig. 4C). When the number of DEDTC injections was reduced to three,
this effect was less pronounced but still evident (data not shown).
Throughout the whole fasting period before glucose injection,
blood glucose concentration was markedly higher in vehicle-
treated Cav2.3-deﬁcient compared to vehicle-treated wild-type
mice (Fig. 4D), further supporting the concept of age-dependent
metabolic changes in one of the two genotypes. However, this
discrepancy with the above ﬁndings (i.e. reduced or normal fasting
glucose in 5 and 10 weeks old Cav2.3-deﬁcient mice respectively)
could also be related to gender-speciﬁc differences, as addressed
later. In any event, DEDTC-treatment appeared to potently stimulate
glucose mobilization in both genotypes, and this effect was more
pronounced in wild-type mice (Fig. 4E). Within the following 6 h,
only wild-type mice were capable to lower their blood glucose
after DEDTC treatment to the level observed in vehicle-treated litter-
mates, while it was still markedly increased immediately prior
to glucose injection in DEDTC-compared to vehicle-treated Cav2.3-
deﬁcient mice (Fig. 4E).
Assuming that Zn2+ chelation produces both, Cav2.3-dependent and
unspeciﬁc effects, additional experiments were carried out with lower
doses of DEDTC. To account for possible gender-speciﬁc differences,
these experiments were performed in parallel with age-matched male
and female mice of both genotypes.
3.5. Ablation of Cav2.3 channels is associated with changes in the
gender-speciﬁc metabolic response to Zn2+-chelation
During treatment with three consecutive injections of 0.025 mg/g
b.w. DEDTC (Fig. 5A), blood glucose level still increased in both geno-
types, but the effect was signiﬁcantly more pronounced in wild-type
mice after 30 (p b 0.05 for both male and female mice) and 60 min
(p b 0.05, only female mice) (Fig. 5B–G). Thereafter, blood glucose
level started to decline again and after 120 and 180 min, similar values
were reached in both genotypes. Strikingly, the lower dose DEDTC
treatment also revealed a marked gender-speciﬁc difference in the
effects of Zn2+ chelation, as the relative increase of blood glucose level
was much more transient and less pronounced in male mice (Fig. 5B &
Fig. 5. Effects of Zn2+ chelation on fasting blood glucose level in Cav2.3-deﬁcient and wild-type mice. A. Experimental protocol: Under conditions of starvation, three injections of DEDTC
(0.025mg/g, i.p.)were carried out at the indicated time points andglucose levels in blood samples taken from the tail veinweremonitored over a period of 3 h. B. Time course of changes in
blood glucose level duringDEDTC treatment in female Cav2.3-deﬁcient (n=8) andwild-type (n=9)mice. Values are normalized to the blood glucose levelmeasured immediately before
the ﬁrst DEDTC injection. C. Time course of changes in blood glucose level during DEDTC treatment inmale Cav2.3-deﬁcient (n= 8) andwild-type (n=9)mice. Values are normalized to
the blood glucose level measured before the ﬁrst DEDTC injection. D. Comparison of blood glucose levels before (left) and 1 h after (right) the ﬁrst DEDTC injection in female
Cav2.3-deﬁcient andwild-type animals (same data as in B). Note the signiﬁcant difference between baseline glucose levels in the two genotypes. E. Comparison of individual normalized
blood glucose levels 1 h after the ﬁrst DEDTC injection in female wild-type (left) and Cav2.3-deﬁcient (right) mice (same data as in B and D). Mean values are indicated by vertical bars.
F. Comparison of blood glucose levels before (left) and 1 h after (right) the ﬁrst DEDTC injection in male Cav2.3-deﬁcient and wild-type animals (same data as in C). G. Comparison of
individual normalized blood glucose levels 1 h after theﬁrst DEDTC injection inmalewild-type (left) and Cav2.3-deﬁcient (right)mice (same data as in C and F).Mean values are indicated
by vertical bars. Statistically signiﬁcant differences are indicated by footnotes and are by unpaired Student's t-test (**, p b 0.001).
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ment) of female (Fig. 5D) but not male (Fig. 5F) Cav2.3-deﬁcient mice
was signiﬁcantly higher than in wild-type animals. To further investi-
gate the phenomenon, female mice were chosen to study the effects
of DEDTC on peptide hormone release, and the observation period
was limited to the initial 60 min after the start of the DEDTC treatment,
where signiﬁcant differences in glucose homeostasis were observed.Fig. 6. Effects of Zn2+ chelation on fasting serumpeptide hormone level in Cav2.3-deﬁcient and
DEDTC (0.025mg/g, i.p.) were carried out at the indicated time points and peptide hormone co
(0 h) and 0.5 h after the second (1 h)DEDTC injection. B. Comparison of individual serum glucag
mice (n= 10 for both genotypes). Mean values are indicated by vertical bars. C. Comparison of
in Cav2.3-deﬁcient (n= 7) and wild-type (n= 5) mice. Mean values are indicated by vertical b
treatment in Cav2.3-deﬁcient (n=8) andwild-type (n=7)mice.Mean values are indicated by
(right) levels after DEDTC treatment in Cav2.3-deﬁcient and wild-type mice (same data as in
Student's t-test (*, p b 0.05).3.6. Zn2+ chelation produces a glucagon response in wild-type but not
Cav2.3-deﬁcient mice
One hour after starting DEDTC treatment in fasted female mice
(Fig. 6A), blood glucose level again reached a signiﬁcantly higher level
in wild-type mice (p b 0.05), while basal glucose level (i.e. before
DEDTC-treatment) was signiﬁcantly higher in Cav2.3-deﬁcient micewild-typemice. A. Experimental protocol: Under conditions of starvation, two injections of
ntent was quantiﬁed in blood samples taken from the tail vein immediately before the ﬁrst
on levels before (left) and after (right) DEDTC treatment in Cav2.3-deﬁcient andwild-type
individual serum somatostatin (SST) levels before (left) and after (right) DEDTC treatment
ars. D. Comparison of individual serum insulin levels before (left) and after (right) DEDTC
vertical bars. E. Comparison of normalized serumglucagon (left), insulin (middle), and SST
B–D). Statistically signiﬁcant differences are indicated by footnotes and are by unpaired
Table 2
Effect of DEDTC-mediated Zn2+ chelation on blood glucose concentration under condi-
tions of starvation. Data are pooled mean ± SEM values from the experiments shown in
Figs. 5–7. Statistically signiﬁcant differences betweenwild-type and Cav2.3-deﬁcient mice
are indicated by footnotes and are by unpaired Student's t-test (**, p b 0.01; *, p b 0.05).
Gender Genotype Time Blood glucose
[h] [mg/dl] [% of baseline] n
Female Wild type 0 104 ± 2** 100 27
0.5 294 ± 18** 273 ± 18** 15
1 312 ± 12** 302 ± 15** 25
3 193 ± 11** 178 ± 12** 15
Cav2.3(−/−) 0 127 ± 4** 100 27
0.5 292 ± 14** 224 ± 14** 17
1 292 ± 12** 232 ± 10** 27
3 248 ± 16** 189 ± 13** 17
Male Wild type 0 135 ± 9** 100 9
0.5 302 ± 42** 221 ± 23** 9
1 266 ± 30** 197 ± 18** 9
3 211 ± 30** 153 ± 15** 9
Cav2.3(−/−) 0 141 ± 13** 100 8
0.5 177 ± 24** 129 ± 15** 8
1 225 ± 32** 161 ± 17** 8
3 169 ± 24** 120 ± 16** 8
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level relative to wild-type mice (Fig. 6D & E) indicating that insulin hy-
persecretion detected in isolated islets from Cav2.3-deﬁcient mice was
not or not entirely due to a lack of neurally mediated effects. DEDTC
Zn2+ chelation conversely decreased serum insulin level in both geno-
types, but this effect was much more pronounced and statistically
signiﬁcant only in Cav2.3-deﬁcient mice (p b 0.05). Zn2+ potently sup-
presses hepatic insulin uptake [7], so that the insulin lowering effect
of DEDTC Zn2+ chelation in both genotypes was presumably mainly
due to increased insulin clearance. However, serum insulin level is
also affected by the degree of SST-suppression of insulin secretion, and
δ-cell STT-release has been shown to involve Cav2.3 channels. As illus-
trated in Fig. 6C, there was no difference in basal SST level and DEDTC
stimulated SST secretion in both genotypes, but this effect was reduced
by approximately half in Cav2.3-deﬁcient mice (Fig. 6C & E). Thus,
increased SST suppression of insulin secretion likely contributed to
reduced serum insulin level in both genotypes, but it couldn't account
for the stronger insulin lowering effect of DEDTC in Cav2.3-deﬁcient
mice (andmay in fact even have led to an underestimation of the differ-
ence between the two genotypes). Glucagon conversely stimulates
insulin secretion [26], and DEDTC increased serum glucagon level by
24% in wild-type and only 6% in Cav2.3-deﬁcient mice (Fig. 6B). Hence,
part of the genotype-dependent difference in DEDTC effects on insulin
level could have been secondary to the stronger glucagon increasing
effects of DEDTC in wild-type mice. As Zn2+ disinhibition of glucagon
secretion requires both, low blood glucose levels and pre-existing inhi-
bition of glucagon release [6,27–29] this could explain the transient
nature of DEDTC effects on blood glucose level (Fig. 5B & C). Thus,
Zn2+ chelation was most effective during the ﬁrst treatment, where
both conditions (i.e. low blood glucose and pre-existing Zn2+ inhibi-
tion) were still met. It could also account for the much more pro-
nounced effects in female mice, which exhibit larger α-cell mass and
glucagon content relative to male mice [30,31] and a more pronounced
glucagon response to hypoglycemic stress [32].
The difference between the two genotypes did not reach statistical
signiﬁcance, possibly due to its small magnitude and the relatively
high variability of serum glucagon level in wild-type mice (Fig. 6B).
Since even small changes in glucagon secretion can markedly affectFig. 7. Relationship between blood glucose and serum glucagon level in Cav2.3-deﬁcient and w
DEDTC (0.025 mg/g, i.p.) were carried out at the indicated time points and glucose and glucago
ﬁrst (0 h) and 0.5 h after the second (1 h) DEDTC injection. B. Comparison of blood glucose lev
deﬁcient (n = 17) mice. C. Comparison of serum glucagon levels before (left) and after (ri
D. Comparison of normalized blood glucose (left) and serum glucagon (right) levels after
E. Relationship between blood glucose and serum glucagon levels in Cav2.3-deﬁcient and
0.137 in wild-type animals but no positive correlation with slightly negative slope and a
are indicated by footnotes and are by unpaired Student's t-test (**, p b 0.001; *, p b 0.05glucose homeostasis, additional experiments were carried out with 15
female mice per genotype to obtain a more reliable estimate of DEDTC
effects on α-cell function.
Consistent with our suspicion, basal glucose and glucagon level in
the larger sample were both signiﬁcantly higher in Cav2.3-deﬁcient
compared to wild-type mice (p b 0.001 and p b 0.05 respectively),
whereas DEDTC effects on serum glucagon level were signiﬁcantly
(p = 0.012) more pronounced in wild-type animals (Fig. 7A–D) (see
also Tables 2 and 3 for pooleddata obtained fromdifferent experimental
sets). Thus, ablation of Cav2.3 channels as well as Zn2+ chelation in
wild-type (and to a signiﬁcantly lesser extent also in Cav2.3-deﬁcient)
mice appeared to stimulate glucagon secretion, suggesting that Cav2.3
channels mediate part of the paracrine Zn2+ inhibition of α-cell gluca-
gon secretion. To corroborate these ﬁndings, a correlation analysis was
carried out by plotting individual values of normalized blood glucoseild-type mice. A. Experimental protocol: Under conditions of starvation, two injections of
n levels were quantiﬁed in blood samples taken from the tail vein immediately before the
els before (left) and 1 h after (right) DEDTC treatment in wild-type (n = 15) and Cav2.3-
ght) DEDTC treatment in Cav2.3-deﬁcient and wild-type mice (same animals as in B).
DEDTC treatment in Cav2.3-deﬁcient and wild-type mice (same data as in B and C).
wild-type mice. Linear correlation analysis revealed a correlation with a R2-value of
low R2-value of 0.002 in Cav2.3-deﬁcient animals. Statistically signiﬁcant differences
).
Table 3
Effect of DEDTC-mediated Zn2+ chelation on serum peptide hormones under conditions of starvation. Data are pooled mean ± SEM values from the experiments shown in Figs. 6 and 7.
Statistically signiﬁcant differences between wild-type and Cav2.3-deﬁcient mice are indicated by footnotes and are by unpaired Student's t-test (*, p b 0.05).
Genotype Time Serum glucagon Serum insulin Serum somatostatin
[h] [mg/dl] [% of baseline] n [μg/l] [% of baseline] n [mg/dl] [% of baseline] n
Wild type 0 267 ± 14 100 25 0.40 ± 0.04* 100 7 0.16 ± 0.04 100 5
1 238 ± 9* 127 ± 9 25 0.34 ± 0.07* 91 ± 19 7 0.24 ± 0.06 155 ± 27 5
Cav2.3(−/−) 0 312 ± 18 100 27 0.51 ± 0.07* 100 8 0.15 ± 0.02 100 7
1 311 ± 16 104 ± 5 27 0.30 ± 0.03* 69 ± 16 8 0.19 ± 0.03 128 ± 13 7
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serum glucagon concentration. As shown in Fig. 7E, therewas a positive
correlation between DEDTC effects on glucose and glucagon level in
wild-type (R2 = 0.14) but not in Cav2.3-deﬁcient mice (R2 b 0.002),
conﬁrming that the DEDTC-induced increase of blood glucose level in
wild-type mice was related to enhanced glucagon secretion, and that
this effect was not present in Cav2.3-deﬁcient mice.
4. Discussion
Immunohistochemical and functional studies indicate that Zn2+
sensitive Cav2.3 channels are involved in peptide hormone secretion
and that their ablation is associated with a complex metabolic pheno-
type [14–18]. We investigated the role of Zn2+ for glucose homeostasis
and peptide hormone secretion in wild-type and Cav2.3-deﬁcient mice.
Our most important ﬁndings are (i) that glucose tolerance is preserved
in Cav2.3-deﬁcient mice but highly sensitive to Zn2+ depletion, (ii) that
isolated islets from Cav2.3-deﬁcientmice exhibit increased basal insulin
secretion and (iii) that Zn2+ chelation with low concentrations of
DEDTC evokes a marked glucagon response in wild-type but not
Cav2.3-deﬁcient mice in vivo. Altered Zn2+ homeostasis evidently pro-
duces complex effects on blood glucose homeostasis, but our ﬁndings
in mice are consistent with previous works in that Zn2+-deﬁciency is
primarily associated with increased blood glucose concentrations, and
they show that this is in part due to insufﬁcient Zn2+-suppression of
Cav2.3 channels. As we argue below, Zn2+ can likely affect release of
all pancreatic peptide hormones, although the functional consequences
and temporal characteristics of Zn2+-suppression depend on the role of
Cav2.3 channels in affected cells and presumably on their relative
location and distance to the origin of co-secreted Zn2+.
4.1. Role of Cav2.3 channels for (suppression of) α-cell glucagon secretion
Approximately 30% of net Ca2+ current in mouseα-cells is sensitive
to the R-type antagonist SNX-482 [33], and glucose-induced suppres-
sion of glucagon release is severely impaired in isolated islets from
Cav2.3-deﬁcient mice [16,17]. Also, SNX-482 is ineffective in suppress-
ing glucagon release in wild-type islets at low glucose concentrations,
but it inhibits glucose-induced suppression of glucagon release [16,
34], suggesting that R-type channels are more important for preventing
glucagon release during hyperglycemia than for triggering it during hy-
poglycemia. Consistent with this notion, we found that ablation of
Cav2.3 channels impairs the coupling of glucagon release to blood
glucose level rather than reducing glucagon release per se, leading to
signiﬁcantly higher blood glucose and glucagon levels in Cav2.3-deﬁ-
cient relative to wild-type mice. However, our ﬁndings also provide
convincing evidence that this is due to insufﬁcient Zn2+-suppression
of glucagon secretion, as Cav2.3 channel ablation and Zn2+-chelation
in wild-type mice had very similar effects, while Zn2+-chelation in
Cav2.3-deﬁcient mice was much less effective in increasing glucagon
secretion. Considering their high Zn2+ sensitivity, it is reasonable to as-
sume thatα-cell Cav2.3 channels play a role for Zn2+-induced paracrine
suppression of glucagon secretion during hyperglycemia. In isolated
mouse and rat islets and in living rats, Zn2+ suppresses α-cell electricalactivity and cessation of β-cell Zn2+ release during hypoglycemia has
been proposed as a trigger for glucagon secretion [4–6]. According to
the Zn2+ switch-off hypothesis, glucose-induced insulin and Zn2+
co-secretion is associated with Zn2+-induced opening of α-cell KATP
channels, resulting in hyperpolarization and closure of Ca2+ and Na+
channels (Fig. 8A). Sudden cessation of Zn2+ supply during hypoglyce-
mia signals KATP channels to close and leads to α-cell depolarization
with successive activation of Ca2+ and Na+ channels (Fig. 8B). During
the peak of the resulting action potential (AP), P/Q-type Ca2+ channels
open and trigger glucagon secretion through localized Ca2+ inﬂux. Due
to their intermediate voltage-range for activation Cav2.3 channels have
been proposed to provide sufﬁcient depolarization after KATP channel
closure for subsequent Na+- and L-type Ca2+ channel-dependent AP
ﬁring [33]. This might be especially important in mouse α-cells, which
have very low KATP channel densities [35,36]. The particular importance
of Cav2.3 channels for suppressing glucagon release during hyperglyce-
mia could be explained by the fact that high glucose concentrations can
directly affectα-cell oxidativemetabolism and thereby close KATP chan-
nels [35,37], which has led to the proposal that KATP channel dependent
α-cell depolarization may actually prevent secretion by inactivating
Na+ and Ca2+ channels [34,35,37]. Thus, while electrical activity and
global Ca2+ oscillations remain preserved in the presence of high glu-
cose, the lower peak height of the AP associated with Na+ and Ca2+
channel inactivation could result in reduced P/Q-type channel depen-
dent exocytosis. Ca2+ oscillations are usually indicative of low-voltage
activated (LVA) Ca2+ channels, which support repetitive Ca2+ inﬂux
at negative resting membrane potentials. However, depolarization suf-
ﬁcient for partial Na+ channel inactivation should produce complete
LVA Ca2+ channel inactivation, and since Cav2.3 channels inactivate at
somewhatmore depolarized potentials and arewell known for their in-
volvement in neuronal pacemaking, one could speculate that they are
required for maintaining α-cell electrical activity in the presence of
high glucose. However, there is also evidence that under physiological
conditions, mouse α-cells express no LVA Ca2+ channels [33], and the
concept that KATP channel dependentα-cell depolarization prevents se-
cretion is challenged by the observation that glucose or tolbutamide-
induced closure of KATP channels stimulates Ca2+ inﬂux and glucagon
secretion in isolated mouse and rat α-cells [38–41]. Instead, the inhibi-
tory action of glucose under hyperglycemic conditions could primarily
depend on β-cell Zn2+ release and suppression of α-cell Cav2.3 chan-
nels, consistent with the observation that glucose challenge is associat-
ed with a paradoxical stimulation of glucagon secretion in Cav2.3-
deﬁcient mice [16]. It is also worth mentioning that SST has been
shown to suppress cloned Cav2.3 channels by a G-protein-dependent
pathway [42] (Fig. 8), suggesting that their native counterparts in
mouse α-cells could play a role for SST suppression of glucagon secre-
tion [34,43]. As previous studies show that SST mediates tonic but not
glucose-induced inhibition of glucagon secretion [34,41], the apparent
lack of SNX-482 effects on wild-type islets in low glucose could then
also reﬂect the fact that the experimental conditions (i.e. static incuba-
tions with possible SST accumulation) are already associated with
complete SST inhibition of Cav2.3 channels.
Finally, it should be acknowledged that the relevance of α-cell
Cav2.3 channels has been questioned, since α-cells isolated from
Fig. 8. Schema of putative Zn2+-mediated functional coupling between insulin and glucagon release. A. In the presence of normal or high blood glucose concentrations, ATP level inβ-cells
increases, leading to closure of KATP channels, depolarization and co-secretion of insulin and Zn2+. In downstreamα-cells, Zn2+ counteracts glucagon release by activation of KATP channels
and inhibition of Cav2.3 channels. B. Under conditions of hypoglycemia, ATP level in β-cells decreases, leading to disinhibition of KATP channels, K+ efﬂux and thus hyperpolarization with
closure of voltage-gated Ca2+ channels. The resulting switch off of Zn2+ release from upstream β-cells is associated with closure of KATP channels and disinhibition of Cav2.3
channels in α-cells and ultimately triggers release of glucagon. For further description see text.
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Ca2+ currents nor changes in single-cell glucagon exocytosis [16]. One
could argue that this is due to compensatory up-regulation of other
(less Zn2+ sensitive) α-cell VGCCs. However, recent large scale patch
clamp analysis of identiﬁed mouseα-cells in a pancreatic slice prepara-
tion indicates that there is actually a wide range of electrophysiological
properties due to heterogeneous α-cell ion channel arrangement [36].
Thus, insufﬁcient or biased α-cell sampling could also explain the ap-
parently unchanged whole-cell Ca2+ current as well as other inconsis-
tencies in the reported ion channel arrangement of mouse α-cells.
These ﬁndings make it tempting to speculate that there are different
α-cell populations with distinct glucose, Zn2+ and SST sensitivities,
which could be recruited in response to different metabolic conditions.
4.2. Role of Cav2.3 channels for (suppression of) β-cell insulin secretion
GSIS is thought to reﬂect interaction between a triggering pathway
of fast insulin secretion (ﬁrst phase insulin response), and an amplifying
pathway of sustained release (second phase insulin response), which is
still only poorly characterized. Here, we reafﬁrm earlier studies by us
and others [16,17] that the sustained peripheral insulin response is sig-
niﬁcantly reduced in adult Cav2.3-deﬁcient mice in vivo. However, our
present ﬁndings also demonstrate that isolated islets from these mice
exhibit normal GSIS and basal hyperinsulinemia relative to islets from
wild-type mice. Increased basal insulin secretion in isolated islets
could reﬂect β-cell-intrinsic functional changes, altered islet-intrinsic
β-cell regulation or a combination of both. We are currently investigat-
ing if reduced Zn2+ feedback inhibition contributes to basal insulinhypersecretion, but our present data are clearly insufﬁcient to exclude
alternative explanations. If Zn2+ feedback inhibition is involved, this
could explain the lack of apparent effects of Cav2.3 channel ablation
on GSIS in isolated islets, since Zn2+ accumulation during static incuba-
tions in high glucose should prevent any contribution of these channels
in wild-type mice. However as mentioned above, SST inhibits recombi-
nant Cav2.3 channels [42] and SNX-482 has been shown to prevent SST
inhibition of insulin secretion from insulinoma cells [44]. It is therefore
likely that Cav2.3 channels are involved in tonic SST suppression of
β-cell insulin secretion (Fig. 8), lack of which could also explain or
contribute to the basal hyperinsulinemia. In any case, our ﬁndings
indicate that β-cell Cav2.3 channels are involved in suppression of
basal insulin secretion, and that this may serve to ﬁne-tune the glu-
cose set-point for insulin secretion. Basal serum insulin level is only
moderately but consistently increased in Cav2.3-deﬁcient relative
to wild-type mice [14,16,17], possibly indicating that islet-extrinsic
factors counterbalance intrinsic hyperinsulinemia to keep serum in-
sulin levels below the detrimental range. The apparent contrast be-
tween intact GSIS in isolated islets and impaired peripheral insulin
response could be indicative of β-cell desensitization, akin to impair-
ments of the sustained insulin response observed in vivo or during
pancreas perfusion in diabetic rats [45,46], which are commonly re-
versed during islet isolation [47,48]. Alternatively, neurally mediated
negative feedback loops, possibly acquired in response to elevated
non-stimulated secretion (i.e. insulin feedback inhibition of GSIS),
may be lost when the pancreas is denervated [49–51] or additional
islet-extrinsic changes in Cav2.3-deﬁcient mice (i.e. altered auto-
nomic control of insulin secretion) may exist [15,52]. A role of
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glucose homeostasis has previously been excluded based on the
potent reduction of GSIS in inbred NMRImice by SNX-482 [16]. How-
ever, this is put into question by the fact that the SNX-482 concentra-
tion used (100 nM) can affect several other ion channels as well [53,
54], which might explain why late GSIS is reduced by 80% in SNX-
482-treated pancreata from NMRI mice, but only by 50% in pancreata
from Cav2.3-deﬁcient mice [16]. The 50% reduction of late GSIS ob-
served during in-situ pancreas perfusion in Cav2.3-deﬁcient mice
on the other hand corresponds well with our in vivo data, and indi-
cates that the impaired peripheral insulin response is not due to in-
creased postprandial insulin clearance. Rather, our study suggests a
causative role for excessive insulin release and depleted insulin
stores, akin to β-cell exhaustion in rodent models of T2DM, where
loss of GSIS is often preceded by excessive insulin secretion [55,56].
In this context, it is particular intriguing that transiently (48 h) up-
regulating insulin secretion in non-diabetic rats sufﬁciently to
lower β-cell insulin content has been shown to selectively reduce
the second phase insulin response by 50% [57]. In any event, our ﬁnd-
ings suggest that Cav2.3 channel dysfunction per se is associated
with basal hyperinsulinemia and possibly increased glucose sensitiv-
ity but normal glucose responsiveness of islet insulin secretion.
4.3. Pathophysiological implications
Our present ﬁndings reveal that immature and young adult Cav2.3-
deﬁcient mice display several characteristic features of pre-diabetes, a
state where glucose homeostasis is altered but glycemic control
still preserved and which commonly precedes development of
T2DM. Interestingly, insulin resistance seems to play no causative
role in Cav2.3-deﬁcient mice, as the response to insulin injection in
10 weeks old animals is unaffected [17] and as glucose tolerance is
preserved3 even despite markedly reduced peripheral insulin re-
sponse (present investigation). We can currently not explain these
ﬁndings, but adequate Zn2+ levels seem to be critical for preserva-
tion of normal glucose tolerance, since the response to glucose chal-
lenge is markedly impaired in Zn2+-depleted Cav2.3-deﬁcient mice.
Zn2+ possesses a wide array of insulin-like effects in vitro [58–64],
appears to be effective as insulinmimetic in adipocytes from diabetic
rats and has been shown to induce normoglycemia in streptozocin-
treated rats in vivo [65]. Hence, insulin-like Zn2+ effects could con-
ceivably counterbalance the decreased peripheral insulin response
of Cav2.3-deﬁcient mice to glucose challenge. This could be imagined
to occur through an increase in the vesicular Zn2+:insulin ratio sec-
ondary to the partial depletion of insulin stores observed in isolated
islets, a process which should be highly sensitive to Zn2+-depletion
or loss of β-cell function (i.e. of insulin and Zn2+-cosecretion). It
could thus explain the apparent age-dependent deterioration of gly-
cemic control in Cav2.3-deﬁcient mice, as reﬂected in the progres-
sion from reduced to elevated mean body weight (see Table 1) and
fasting glucose level. This is reinforced by previous reports that
Cav2.3-deﬁcient mice develop symptoms of T2DM, including over-
weight, insulin resistance and glucose intolerance [14]. These ﬁnd-
ings are somewhat difﬁcult to interpret, since mice of various ages
(12–50 weeks) were used without appropriate age-matching or dis-
crimination betweenmale and female animals. The concept is never-
theless intriguing, as several studies have since linked variants in the
gene encoding Cav2.3 channels to impaired glucose homeostasis in
human T2DM patients [66–68]. Most notably, the region on chromo-
some 1q21–25, where the human Cav2.3 gene is located, has been
linked to young-onset T2DM in Pima Indians [67]. Subjects with3 Initial reports from our lab indicated that these mice are glucose intolerant [15], but
we can now statewith certainty that theseﬁndings are attributable to the use ofmicewith
different genetic backgrounds (i.e. a higher glucose tolerance of C57Bl/6 control mice)
rather than to ablation of Cav2.3 channels.the risk allele display signiﬁcantly higher blood glucose concentra-
tions 30min, 60 min, and 120min after glucose challenge and higher
mean fasting insulin and glucose levels than control persons [67].
Also, high fasting plasma insulin concentrations interestingly predict
T2DM in Pima Indians independent of insulin resistance, suggesting
a causative role of basal hyperinsulinemia [69]. Our ﬁndings indicate
that Zn2+ supplementation could in these cases possibly preserve
glucose tolerance, and that close monitoring and/or manipulation
of blood Zn2+ levels may provide a general interventional approach
for treatment in certain patient populations with T2DM.
4.4. Limitations and relevance of the present work
Several approaches have been used to investigate the role of Zn2+
for pancreatic islet crosstalk, including single cell preparations, tissue
slices, isolated islets of Langerhans and in vivo studies. We used Zn2+-
chelation in living mice, an approach which circumvents many of the
problems associated with in vitro preparations but clearly has its own
inherent limitations, resulting mainly from the complex actions of
Zn2+ throughout the whole body. Combined with the use of genetically
modiﬁed mice however, it provides the opportunity to study Zn2+
effects associated with a particular protein target in a physiologically
relevant context. Our present study is clearly not suited nor was it
intended to uncover all of the complex molecular alterations of glucose
homeostasis in Cav2.3-deﬁcient mice. Rather it provides ﬁrst evidence
for the in vivo relevance of Cav2.3 channels in the context of Zn2+, and
a reference point for further in vitro and in vivo studies. Although
DEDTC is regarded a preferential Zn2+-chelator, we cannot however,
exclude that chelation of other physiologically relevant metal ions,
such as Cu2+ or Mn2+ may have contributed to the observed effects
[70]. Due to its membrane-permeant nature, DEDTC may moreover
have inﬂuenced intracellular signaling cascades or metal-dependent
enzymes. However, it has been suggested that Zn2+ is more easily che-
lated by DEDTC after being released into the extracellular space [71] so
that the low dose regimen used in the present study should have mini-
mized unspeciﬁc effects, like abstraction of Zn2+ from metalloproteins
or intracellular stores.
5. Conclusion
The present study reveals that Zn2+ inhibition of Cav2.3 voltage-
gated Ca2+ channels contributes to suppression of glucagon secretion
during hyperglycemia and indicates that these channels may serve as
a general target for (differential) feedback inhibition of pancreatic pep-
tide hormone secretion by Zn2+ and possibly SST. We also demonstrate
that Cav2.3-deﬁcient mice display signs of pre-diabetes followed by a
progressive loss of glycemic control, making them a valuable model
for certain aspects of human T2DM. Thus, our present ﬁndings indicate
that maintenance of adequate Zn2+ levels may be critical for normal
glucose tolerance in patients with T2DM linked to Cav2.3 channel
dysfunction.
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